2,593 Shares in Revolution Medicines, Inc. $RVMD Acquired by Vise Technologies Inc.

Vise Technologies Inc. acquired a new stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 2,593 shares of the company’s stock, valued at approximately $486,000.

Other hedge funds also recently bought and sold shares of the company. Alphabet Inc. bought a new stake in shares of Revolution Medicines during the second quarter worth $551,843,000. Norges Bank bought a new position in shares of Revolution Medicines in the fourth quarter worth about $195,568,000. Avoro Capital Advisors LLC bought a new position in shares of Revolution Medicines in the fourth quarter worth about $172,840,000. UBS Group AG increased its stake in Revolution Medicines by 183.6% in the 4th quarter. UBS Group AG now owns 3,087,937 shares of the company’s stock worth $245,954,000 after buying an additional 1,998,972 shares during the period. Finally, Polar Capital Holdings Plc increased its stake in Revolution Medicines by 321.2% in the 4th quarter. Polar Capital Holdings Plc now owns 2,013,791 shares of the company’s stock worth $160,398,000 after buying an additional 1,535,686 shares during the period. Institutional investors own 94.34% of the company’s stock.

Revolution Medicines Stock Up 1.0%

NASDAQ:RVMD opened at $211.58 on Tuesday. Revolution Medicines, Inc. has a 1-year low of $35.62 and a 1-year high of $220.34. The company has a 50-day moving average of $189.02 and a 200 day moving average of $145.65. The firm has a market cap of $45.35 billion, a PE ratio of -23.99 and a beta of 1.39. The company has a debt-to-equity ratio of 0.40, a current ratio of 11.38 and a quick ratio of 11.38.

Revolution Medicines (NASDAQ:RVMD) last issued its earnings results on Wednesday, August 5th. The company reported ($3.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.04) by ($1.02). During the same period in the prior year, the company posted ($1.31) EPS. As a group, research analysts anticipate that Revolution Medicines, Inc. will post -8.82 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

RVMD has been the subject of several research reports. Guggenheim boosted their price objective on shares of Revolution Medicines from $235.00 to $240.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Evercore reaffirmed an “outperform” rating and set a $230.00 target price on shares of Revolution Medicines in a research report on Thursday, August 6th. Royal Bank Of Canada lifted their price target on shares of Revolution Medicines from $182.00 to $203.00 and gave the company an “outperform” rating in a research note on Thursday, August 6th. Mizuho boosted their price target on Revolution Medicines from $185.00 to $215.00 and gave the company an “outperform” rating in a report on Monday, July 6th. Finally, Wedbush increased their price objective on Revolution Medicines from $192.10 to $201.00 and gave the stock an “outperform” rating in a research note on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $167.89.

Insider Activity

In other Revolution Medicines news, insider Stephen Michael Kelsey sold 4,175 shares of the company’s stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $156.12, for a total transaction of $651,801.00. Following the completion of the sale, the insider owned 291,876 shares in the company, valued at $45,567,681.12. This represents a 1.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Jack Anders sold 20,000 shares of the company’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $168.33, for a total value of $3,366,600.00. Following the sale, the chief financial officer owned 123,269 shares of the company’s stock, valued at approximately $20,749,870.77. This represents a 13.96% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 132,497 shares of company stock valued at $21,470,486. 7.60% of the stock is currently owned by corporate insiders.

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.